{"id":"W3174706170","doi":"10.1016/j.ejca.2021.05.025","title":"Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Saskatchewan Cancer Agency; BC Cancer Agency; Jewish General Hospital","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; MacroGenics; Silverback Therapeutics; Pfizer; NuCana; Regeneron Pharmaceuticals; Mylan; Unum Therapeutics; Helsinn Therapeutics; Amgen; Radius Health; Syndax Pharmaceuticals; Clovis Oncology; Teva Pharmaceutical Industries; Helsinn; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Eli Lilly and Company; AstraZeneca; Foundation Medicine; National Cancer Research Institute; Genomic Health; Mersana Therapeutics; Karyopharm Therapeutics; Puma Biotechnology","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Human Epidermal Growth Factor Receptor 2; Internal medicine; Placebo; Breast cancer; Cancer; Pathology; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006373321,0.0007655699,0.001709091,0.0001993087,0.0002150082,0.0007821774,0.0003817187,0.0006730388,0.003068656],"category_scores_gemma":[0.0006988735,0.0002435064,0.001502484,0.0002422425,0.0004278329,0.000529148,0.0002654934,0.001828516,0.0002892116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005227026,"about_ca_system_score_gemma":0.0004228264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009009255,"about_ca_topic_score_gemma":0.002334601,"domain_scores_codex":[0.9997744,0.0001156297,0.00001309778,0.00003989427,0.00001143626,0.00004548606],"domain_scores_gemma":[0.9998261,0.00004587234,0.00004136177,0.000009200534,0.000008215576,0.0000692375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9378827,0.002780164,0.003104216,0.0007773943,0.002086708,0.0001079363,0.0000618654,0.001375249,0.006039363,0.0001495501,0.001708766,0.04392598],"study_design_scores_gemma":[0.7636341,0.1819226,0.04313274,0.0001636512,0.003576508,0.0002959358,0.0001131615,0.001907547,0.001858725,0.0004109622,0.002940132,0.00004392874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925166,0.004703174,0.000133072,0.0005123071,0.0002392271,0.0001438444,0.0004995364,0.00003250944,0.001219757],"genre_scores_gemma":[0.9963545,0.001532129,0.0001869867,0.0002835879,0.0001482818,0.0001494177,0.0005831606,0.000005381193,0.0007566658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003068656,"threshold_uncertainty_score":0.01026565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05052952878100639,"score_gpt":0.3440817760243052,"score_spread":0.2935522472432988,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}